Study on the correlation between KCNJ11 gene polymorphism and metabolic syndrome in the elderly

Jiang, Fan; Liu, Ning; Chen, Xiao Zhuang; Han, Kun; Zhu, Cai Zhong

doi:10.3892/etm.2017.4714

Cited by 2 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…KCNJ11 gene polymorphisms have been linked to T2DM in patients from various parts of China ( Gao et al, 2014). The KCNJ11 gene polymorphism and type 2 diabetes are associated in the elderly with metabolic syndrome (Fan et al, 2017). Two SNPs genotyped inside KCNJ11, on the other hand, showed significance associations with T2DM in a meta-analysis study (Qin etal .,2013 (.…”

Section: Introductionmentioning

confidence: 99%

The Association Between genetic variations of KCNj11 gene and type 2 diabetes mellitus in a sample of Iraqi population.

Hussieny

Alsahlawi

2023

Bio. Jour.

View full text Add to dashboard Cite

Background: Type 2 diabetes mellitus is a polygenic disorder that develops as a result of a complex interaction between multiple genes and environmental factors. KCNJ11 gene encodes a Kir6.2 protein which forms the inner section of the potassium channels in pancreatic beta cells. Methods: This case-control study involved 300 T2DM patients and 300 healthy controls. The KCNJ11 rs5215 and rs5210 polymorphism was genotyped by Restriction Fragment Length Polymorphism (RFLP). Results : Hardy Weinberg equation statistics of KCNJ11 rs5210 (A/G) SNP genotypes among patients, control subjects highly significant (p < 0.001). Comparison of KCNJ11 rs5210 (A/G) SNP genotypes the codominance model, the additive model The recessive model and has shown no significant variation between control and patient groups (p = 0.564), (p = 0.806)and (p = 0.284) respectively. confirmed the lack of significant association (p = 0.589). Analysis of alleles has shown no significant association (p = 0.432). Comparison of BMI and HDL is significant to KCNJ11 rs5210 (A/G) SNP genotypes based on codominance model and other biochemical is not . Hardy Weinberg equation statistics of KCNJ11 rs5215 (C:I /T:V) SNP genotypes among patients, control highly significant (p < 0.001). The codominance model has shown no significant difference (p =0.835). The dominant model, the recessive model and the additive model has shown no significant difference (p =0.581),(p =0.606) and (p =0.483). Allele analysis has shown no significant difference (p =0.463). Comparison of BMI and cholesterol is no significant to KCNJ11 rs5215 (C/T) SNP genotypes based on codominance model and other biochemical is significant. The association between risk of disease and haplotypes resulting from KCNJ11 rs5210 (A/G) versus rs5115 (C:I /T:V) interaction is H 1 , H2 haplotypes was associated with highly significant risk of disease (p = 0.004) OR of 1.64, (p < 0.001) with an OR of 0.35. H 3 haplotypes was associated with significant protection against the disease (p = 0.024) with an approximate OR of 0.69. The presence of H 4 haplotypes was associated with highly significant risk of the disease (p < 0.001) with an OR of 2.52. Conclusions: This study showed that rs5215and rs5210 polymorphism of the KCNJ11 gene is an important risk factor for type 2 diabetes mellitus in a sample of the Iraqi population. Aimed of study :This study was aimed to detect the relationship between the rs5215and rs5210 polymorphism of the KCNJ11 associated with T2DM in Iraqi population ,what is the impact of haplotype analysis on the risk of T2DM as well as the glycemic indices.

show abstract

Section: Introductionmentioning

confidence: 99%

The Association Between genetic variations of KCNj11 gene and type 2 diabetes mellitus in a sample of Iraqi population.

Hussieny

Alsahlawi

2023

Bio. Jour.

View full text Add to dashboard Cite

show abstract

Neurodegenerative pathways as targets for acquired epilepsy therapy development

2020

View full text Add to dashboard Cite

There is a growing body of clinical and experimental evidence that neurodegenerative diseases and epileptogenesis after an acquired brain insult may share common etiological mechanisms. Acquired epilepsy commonly develops as a comorbid condition in patients with neurodegenerative diseases such as Alzheimer's disease, although it is likely much under diagnosed in practice. Progressive neurodegeneration has also been described after traumatic brain injury, stroke, and other forms of brain insults. Moreover, recent evidence has shown that acquired epilepsy is often a progressive disorder that is associated with the development of drug resistance, cognitive decline, and worsening of other neuropsychiatric comorbidities. Therefore, new pharmacological therapies that target neurobiological pathways that underpin neurodegenerative diseases have potential to have both an anti-epileptogenic and diseasemodifying effect on the seizures in patients with acquired epilepsy, and also mitigate the progressive neurocognitive and neuropsychiatric comorbidities. Here, we review the neurodegenerative pathways that are plausible targets for the development of novel therapies that could prevent the development or modify the progression of acquired epilepsy, and the supporting published experimental and clinical evidence. K E Y W O R D SAMPA, amyloid-β, glutamate, mTOR, neuroinflammation, tau

show abstract

Study on the correlation between KCNJ11 gene polymorphism and metabolic syndrome in the elderly

Cited by 2 publications

References 22 publications

The Association Between genetic variations of KCNj11 gene and type 2 diabetes mellitus in a sample of Iraqi population.

The Association Between genetic variations of KCNj11 gene and type 2 diabetes mellitus in a sample of Iraqi population.

Neurodegenerative pathways as targets for acquired epilepsy therapy development

Contact Info

Product

Resources

About